{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Rectal+Adenocarcinoma", "query": { "condition": "Locally Advanced Rectal Adenocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 100, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Rectal+Adenocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T03:08:24.904Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02788279", "title": "A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2016-07-05", "completion_date": "2018-12-26", "has_results": true, "last_update_posted_date": "2019-12-11", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 17, "location_summary": "Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788279" }, { "nct_id": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "NSCLC", "Non Small Cell Lung Cancer", "NSCLC, Recurrent", "Non-Small Cell Squamous Lung Cancer", "Pancreas Cancer", "Pancreatic Neoplasm", "Colorectal Adenocarcinoma", "CRC", "Colon Cancer", "Rectal Cancer", "Cancer", "Ovarian Cancer", "Ovarian Neoplasms", "Mesothelioma", "Mesothelioma, Malignant", "Ovary Cancer", "Lung Cancer", "MESOM" ], "interventions": [ { "name": "A2B694", "type": "BIOLOGICAL" }, { "name": "A2B543", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2024-04-03", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 12, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051695" }, { "nct_id": "NCT02921256", "title": "Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Stage II Rectal Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 363, "start_date": "2017-01-11", "completion_date": "2023-09-20", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 645, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921256" }, { "nct_id": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2019-02-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 21, "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 16 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821935" }, { "nct_id": "NCT00462501", "title": "Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2007-03", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00462501" }, { "nct_id": "NCT00527111", "title": "Pre-op Rectal ChemoRad +/- Cetuximab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Pelvic irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2007-02", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-11-03", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 41, "location_summary": "Tucson, Arizona • Melbourne, Florida • Miami, Florida + 36 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Niles", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00527111" }, { "nct_id": "NCT02270606", "title": "Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucinous Adenocarcinoma of the Rectum", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Rectum", "Rectal Adenocarcinoma", "Stage IIA Rectal Cancer", "Stage IIB Rectal Cancer", "Stage IIC Rectal Cancer", "Stage IIIA Rectal Cancer", "Stage IIIB Rectal Cancer", "Stage IIIC Rectal Cancer" ], "interventions": [ { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2014-12-04", "completion_date": "2021-05-13", "has_results": false, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270606" }, { "nct_id": "NCT00086931", "title": "Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2003-09", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2013-03-08", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00086931" }, { "nct_id": "NCT05678257", "title": "A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Adenocarcinoma", "Colorectal Cancer Metastatic", "Neoplasm, Colorectal" ], "interventions": [ { "name": "Fosifloxuridine Nafalbenamide", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NuCana plc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2023-04-18", "completion_date": "2024-08-29", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 16, "location_summary": "Newark, Delaware • Washington D.C., District of Columbia • Gainesville, Florida + 12 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05678257" }, { "nct_id": "NCT04511039", "title": "Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A", "Locally Advanced Colorectal Carcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma", "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" }, { "name": "Talazoparib Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-06-08", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-22T03:08:24.904Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04511039" } ] }